Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTIMATE-LM
NCT05650411Recruiting
- Start
- Apr 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in coronary arteriosclerosis (2 arms). Primary endpoint: Patient-oriented composite endpoint at 2 years. Started Apr 2026; status: recruiting.
02
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NCT05650411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650411.